Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas--a prospective, randomized study
| Autor: | Elber S. Camacho, David W. Wilbur, George H. Petti, Dennis A. Hilliard, Robert E. Rentschler, Ric B. Thorpe, George D. Chonkich |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty law.invention Random Allocation Randomized controlled trial law Carcinoma medicine Humans Combined Modality Therapy Prospective Studies Stage (cooking) Prospective cohort study Aged Postoperative Care business.industry Middle Aged medicine.disease Surgery Clinical trial Methotrexate Oncology Head and Neck Neoplasms Toxicity Carcinoma Squamous Cell business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 5:278-285 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1987.5.2.278 |
| Popis: | To determine if adjuvant methotrexate (MTX), escalated weekly to toxicity, could improve disease-free survival (DFS) and overall survival by preventing recurrent disease, 60 patients with potentially resectable stage III or IV squamous head and neck carcinomas were stratified by primary site, stage, and nutritional status, then randomized by pairs to receive or not receive adjuvant MTX. All received standard surgery and postoperative radiation therapy. Five patients were taken off study because of unresectability at the time of surgery, leaving 55 evaluable patients. There were no statistically significant imbalances in known prognostic factors between the two treatment arms. MTX was begun at 40 mg/m2 and escalated 10 mg/m2 weekly (four doses preoperatively; four doses postoperatively, preradiation therapy; eight doses postradiation therapy) to mucosal or hematologic toxicity. The median peak MTX dose achieved was 80 mg/m2. Although three patients were hospitalized with MTX toxicity, none died of MTX toxicity. No patient receiving MTX had disease progression during treatment, and there was no increase in postoperative complications. Thirty-two patients died (median survival, 19 months); 23 patients are alive with median follow-up of 43 months. There was no statistically significant difference in actuarial DFS (P = 1.0) or overall survival (P = .61). Although patients on the MTX arm appeared to have less local and regional recurrences at first recurrence (thus more distant metastases), this did not reach statistical significance (P = .06). There was no significant difference between the sites of recurrence at death or last follow-up (P = .38). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|